{"id":"W2997351648","doi":"10.1200/jco.19.01381","title":"Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Ipilimumab; Discontinuation; Adverse effect; Internal medicine; Hazard ratio; Melanoma; Adjuvant; Cancer; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Surgery; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002782942,0.001121786,0.00147049,0.0003490775,0.0003474033,0.0005344402,0.0008434344,0.0008835143,0.003654766],"category_scores_gemma":[0.0009123689,0.0005705797,0.001138608,0.000326644,0.0009158699,0.0005109405,0.0002946016,0.002522933,0.0008253657],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008031838,"about_ca_system_score_gemma":0.002245581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008537431,"about_ca_topic_score_gemma":0.00285262,"domain_scores_codex":[0.9993994,0.000377228,0.00002340347,0.00008341284,0.00004928764,0.00006721324],"domain_scores_gemma":[0.9991196,0.0001652641,0.0001716318,0.0000663317,0.00004452005,0.0004326816],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8882712,0.04778441,0.004674121,0.0003933168,0.0007129033,0.00008610378,0.00007984674,0.001624154,0.01413077,0.0002950331,0.002415397,0.03953289],"study_design_scores_gemma":[0.7223739,0.2651889,0.006940988,0.00002850192,0.000263398,0.00008500335,0.00002611453,0.001067454,0.001681865,0.0002813101,0.002047118,0.00001542141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847877,0.002181038,0.001173471,0.0006402133,0.0002630406,0.006417333,0.001529499,0.00007366923,0.002933992],"genre_scores_gemma":[0.9759033,0.001989178,0.004562023,0.001661126,0.0002712696,0.007328064,0.002363993,0.00003540198,0.005885752],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003654766,"threshold_uncertainty_score":0.01471776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07986884141034623,"score_gpt":0.4345343013265612,"score_spread":0.354665459916215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}